Valuation : Provectus Biopharmaceuticals, Inc.

Market Cap 22.53M 19.37M 18.28M 16.65M 31.13M 2.15B 31.41M 218M 83.78M 1.09B 84.59M 82.74M 3.47B P/E 2024
-10.6x
P/E 2025 -4.33x
Enterprise Value 25.25M 21.72M 20.49M 18.67M 34.9M 2.41B 35.21M 244M 93.93M 1.22B 94.84M 92.76M 3.89B EV / Sales 2024
86,451,912x
EV / Sales 2025 78,013,766x
Free-Float
92.52%
Yield 2024 *
-
Yield 2025 -
08-13 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-07 Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose CI
06-25 Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10 CI
06-19 Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call
05-18 Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study RE
05-18 Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study CI
05-14 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-04 Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026 CI
04-02 Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing CI
03-26 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-25 Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
11-13 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
09/10/25 Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy CI

Last Transcript : Provectus Biopharmaceuticals, Inc.

1 day-7.32%
1 week+7.36%
Current month+9.66%
1 month+4.03%
3 months-9.62%
6 months+8.77%
Current year+10.91%
1 week 0.05
Extreme 0.0514
0.07
1 month 0.05
Extreme 0.0513
0.07
Current year 0.04
Extreme 0.038
0.08
1 year 0.04
Extreme 0.038
0.09
3 years 0.04
Extreme 0.038
0.22
5 years 0.03
Extreme 0.034
0.22
10 years 0.01
Extreme 0.011
0.22
Manager TitleAgeSince
Chief Executive Officer 73 15/04/2024
Chief Tech/Sci/R&D Officer 62 14/05/2012
Director of Finance/CFO 59 24/03/2019
Director TitleAgeSince
Chairman 57 02/04/2017
Director/Board Member 78 26/04/2018
Chairman 73 26/04/2018
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Exercice

Chief Executive Officer

-11,328 0.1200%
26/08/26 Exercice

Chief Executive Officer

-11,328 0.1200%
30/06/26 Free

Director

48,917 0.5182%
Change 5-day change 1-year change 3-year change Capi.($)
-7.32%+7.36%-11.43%-43.28% 22.53M
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.23%-3.87%+31.19%+74.70% 62.23B
+1.45%+1.53%-12.05%+383.87% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
+1.48%-6.69%-7.18%-17.91% 24.22B
+0.79%-3.74%+14.41%-19.60% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-3.86%-6.93%+40.57%+149.75% 14.23B
Average -1.18%-2.97%+32.69%+148.99% 27.27B
Weighted average by Cap. -0.13%-3.10%+34.73%+136.35%

Financials

2024 2025
Net sales 0.62 0.53 0.5 0.46 0.85 59 0.86 5.96 2.3 29.93 2.32 2.27 95.06 0.34 0.29 0.27 0.25 0.46 32.13 0.47 3.25 1.25 16.3 1.26 1.23 51.77
Net income -4.76M -4.1M -3.86M -3.52M -6.58M -455M -6.64M -46.02M -17.71M -231M -17.88M -17.49M -734M -5.43M -4.67M -4.41M -4.01M -7.5M -519M -7.57M -52.48M -20.2M -263M -20.39M -19.95M -837M
Net Debt 2.88M 2.47M 2.33M 2.13M 3.98M 275M 4.01M 27.81M 10.7M 140M 10.8M 10.57M 443M 2.73M 2.35M 2.21M 2.02M 3.77M 261M 3.8M 26.36M 10.14M 132M 10.24M 10.02M 420M
Logo Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Employees
6
Date Price Change Volume
10/09/26 US$0.0536 +1.71% 177,617
09/09/26 US$0.0527 -0.75% 52,072
08/09/26 US$0.0531 -11.50% 207,865
04/09/26 US$0.0600 +3.90% 70,811
03/09/26 US$0.0578 -1.45% 7,450
  1. Stock Market
  2. Stocks
  3. PVCT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!